| 翻訳と辞書 |
JWH-133
JWH-133 is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman.
JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers . This anti-inflammatory action is induced through agonist action at cannabinoid receptors, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.
It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.〔http://www.enewspf.com/index.php/latest-news/health-and-fitness/18029-marijuana-compound-halts-breast-cancer-tumor-growth-〕
==Legal Status==
The substance commonly referred to as "JWH-133" is not a scheduled substance in the U.S, except in Alabama.〔(【引用サイトリンク】 title=Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd. )〕 Low abuse potential makes it less likely for regulation relative to its sister drugs such as JWH-018, as JWH-133 is selective for the non-psychoactive CB2 receptor and thus lacks significant psychoactive effects.〔http://www.usdoj.gov/dea/pubs/scheduling.html〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「JWH-133」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|